Author(s)

Alice Maria Garcia Possodeli¹, Barbara Barbosa da Cruz¹, Carolina Miranda Mourao Bastos¹, Gabriel Prates de Almeida Lopes Abelha¹, Joao Jeronymo Barros de Oliveira¹, Marcelli Caroline do Amaral Costa¹, Leilane Maria Moreira Araujo¹, Lucas Vasques de Paula Hobaik¹, Natalie Campello Nideck Albertino¹, Thaynara Rozendo da Silva¹, Rogério Nunes Barreto¹, Marcel Vasconcellos^2*

Affiliation(s)

¹ Medical Graduate Student, School of Medicine, Centro Universitário Serra dos órg?os - UNIFESO, Rio de Janeiro, Brasil. - Acquisition of data.
² Professor of Experimental Research, School of Medicine, Centro Universitário Serra dos órg?os - UNIFESO, Rio de Janeiro, Brasil. - Conception, design, intellectual and scientific content of the study, critical revision.

Corresponding Author

Marcel Vasconcellos

ABSTRACT

Background: Global estimates show that by 2035 we will have about 592 million diabetic patients, with a major impact on low- and middle-income countries. Pancreas and pancreatic islet transplantation are currently the only available therapeutic alternatives capable of restoring the physiological pattern of insulin secretion in diabetic patients. However, because the rate of pancreas transplantation is still very low in the country, a more comprehensive criterion for donor acceptance has been proposed. The therapeutic procedure for transplantation of pancreatic islet is approved in Canada and it is in the approval phase in the United States and in experimental phase in Brazil. Despite the fact that the procedure is minimally invasive, consisting of islet infusion into the hepatic parenchyma by ultrasound-guided transcutaneous catheterization, it was observed that both the function and the survival of the islet deteriorate with time, due to factors related to the revascularization of the grafts. In addition, long-term follow-up allowed the identification of late side effects, such as the development of foci of hepatic steatosis. Aims: To investigate the state of knowledge of pancreatic islet transplantation in murine experimental models. Materials and Methods: A critical analysis of PubMed?-indexed publications from 2000 to May 2019 was performed, associating the following descriptors: "pancreatic islet transplantation", "proliferation", "beta-cell". Results: Of the total of 225 publications, 23 publications were obtained, whose summary or complete access was validated by correlation with the theme. Full articles have been reviewed and references were used to identify other sources of information. Conclusion: The state of the art in transplantation of pancreatic islets, in murine experimental models and their translational use, still presents pending questions. Researchers advocate the need for well-designed and statistically significant prospective studies aimed at solving basic and fundamental issues such as immune tolerance. However, it is believed that in the near future, cell replacement therapy will benefit a greater number of diabetic patients.

KEYWORDS

Diabetes Mellitus; Pancreatic Islet Transplantation; Translational Medical Research; Rodents

CITE THIS PAPER

Alice Maria Garcia Possodeli, Barbara Barbosa da Cruz, Carolina Miranda Mourao Bastos, Gabriel Prates de Almeida Lopes Abelha, Joao Jeronymo Barros de Oliveira, Marcelli Caroline do Amaral Costa, Leilane Maria Moreira Araujo, Lucas Vasques de Paula Hobaik, Natalie Campello Nideck Albertino, Thaynara Rozendo da Silva, Rogério Nunes Barreto, Marcel Vasconcellos. Current status of pancreatic islet transplantation in murine experimental models. literature review. Acta Translational Medicine. 2019, 2(1): 1-6.

REFERENCES

[1]. 21st Brazilian Diabetes Society Congress. Diabetol Metab Syndr 2018; 10(Suppl 1): 27.
[2]. Merani S, Shapiro AM. Current status of pancreatic islet transplantation. Clin Sci (Lond) 2006; 110: 611-25.
[3]. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343(4): 230-8.
[4]. Brazilian Association of Organ Transplantation (ABTO). Numerical data on the donation of organs and transplants performed by state and institution in the period. Brazilian Registry of Transplants. Year XXIV. n. 3. 2018. Available in: http://www.abto.org.br/abtov03/default.aspx?mn=566&c=1118&s=0&friendly=rbt-2018. Accessed: December 11, 2018.
[5]. Salvalaggio PR de O, Perosa M, Figueiró JM. Optimization of the use of pancreatic grafts in Brazil. J Bras Transpl 2005; 8: 390-95.
[6]. Piemonti L, Pileggi A. Islet transplantation. [Updated 2016 Jan 29]. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278966/.
[7]. Lee Y, Ravazzola M, Park BH, Bashmakov YK, Orci L, Unger RH. Metabolic mechanisms of failure of intraportally transplanted pancreatic beta-cells in rats: role of lipotoxicity and prevention by leptin. Diabetes 2007; 56: 2295-301.
[8]. Christoffersson G, Henriksn?s J, Johansson L, Rolny C, Ahlstr?m H, Caballero-Corbalan J, Segersv?rd R, Permert J, Korsgren O, Carlsson P-O, Phillipson M. Clinical and experimental pancreatic islet transplantation to striated muscle. Diabetes 2010; 59(10): 2569-78.
[9]. Eliaschewitz FG, Franco DR, Mares-Guia TR, Noronha IL, Labriola L, Sogayar MC. Islet transplantation in clinical practice: current state and perspectives. Arq Bras Endocrinol Metab 2009; 53(1).
[10]. Chaib E, Papalois A, Brons IGM, Calne RY. Isogenic transplantation of islets of Langerhans in the liver of rats. (Methodology for separation and purification of the islets of Langerhans). Arq Gastroenterol 2000; 37: 44-51.
[11]. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980; 210: 908-10.
[12]. Ricordi C, Lacy PE, Scharp DW. Automated islet isolation from human pancreas. Diabetes 1989; 38(Suppl 1): 140-2.
[13]. Hirabaru M, Kuroki T, Adachi T, Kitasato A, Ono S, Tanaka T, Matsushima H, Sakai Y, Soyama A, Hidaka M, et al. A method for performing islet transplantation using tissue-engineered sheets of islets and mesenchymal stem cells. Tissue Eng Part C Methods 2015; 21: 1205-15.
[14]. Takahashi H, Sakata N, Yoshimatsu G, Hasegawa S, Kodama S. Regenerative and transplantation medicine: cellular therapy using adipose tissue-derived mesenchymal stromal cells for type 1 diabetes mellitus. J Clin Med 2019; 8(2): 249.
[15]. Thompson DM, Meloche M, Ao Z, et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation 2011; 91(3): 373-8.
[16]. Wang P, Fiaschi-Taesch NM, Vasavada RC, et al. Diabetes mellitus – Advances and challenges in human beta-cell proliferation. Nat Rev Endocrinol 2015; 11: 201-21.
[17]. Conrad E, Stein R, Hunter CS. Revealing transcription factors during human pancreatic β-cell development. Trends Endocrinol Metab 2014; 25: 407-14.
[18]. Micklos DA, Freyrer GA, Crotty DA. The Science of DNA. 2nd ed. Porto Alegre, RS: Publisher Artmed, 2005.
[19]. Ferrer J, Benito C, Gomis R. Pancreatic islet GLUT glucose transporter mRNA and protein expression in humans with and without NIDDM. Diabetes 1995; 44: 1369-74.

[20]. Dai C, Brissova M, Hang Y, Thompson C, Poffenberger G, Shostak A, Chen Z, Stein R, Powers AC. Islet-enriched gene expression and glucose-induced insulin secretion in human and mouse islets. Diabetologia 2012; 55(3): 707-18.

[21]. Hoang DT, Matsunari H, Nagaya M, Nagashima H, Millis JM, Witkowski P, et al. A Preserved Rule for Organization of Pancreatic Islets. PLoS ONE 2014; 9(10): e110384.

[22]. Sakata N, Yoshimatsu G, Tsuchiya H, Egawa S, Unno M. Animal models of diabetes mellitus for islet transplantation. Exp Diabetes Res 2012; 2012: 256707.

[23]. Griffin KJ, Thompson PA, Gottschalk M, Kylllo JH, Rabinovitch A. Combination therapy with sitagliptin and lansoprazole in patients with recent onset type 1 diabetes (REPAIR–T1D): 12-month results of a multicentre, randomised placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 2014; 2: 710–718.

[24]. Garcia-Ocana A, Stewart AF. Urging β cells to proliferate for diabetes: why do we need MEN? J Clin Invest 2014; 124: 3698–3700.

[25]. Chamberlain CE, Scheel DW, McGlynn K, Kim H, Miyatsuka T, Wang J, Nguyen V, Zhao S, et al. Menin determines K-RAS proliferative outputs in endocrine cells. J Clin Invest 2014; 124: 4093–4101.

[26]. Berman DM, Molano RD, Fotino C, et al. Bioengineering the endocrine pancreas: intraomental islet transplantation within a biologic resorbable scaffold. Diabetes 2016; 65(5): 1350–61.

[27]. Anazawa T, Okajima H, Masui T, Uemoto S. Current state and future evolution of pancreatic islet transplantation. Ann Gastroenterol Surg 2018; 3(1): 34-42.